{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T18:03:48Z","timestamp":1784052228310,"version":"3.55.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virchows Arch"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s00428-025-04329-6","type":"journal-article","created":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T13:04:03Z","timestamp":1762520643000},"page":"103-112","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Molecular co-alteration patterns of RICTOR-mutant metastatic lung adenocarcinomas: a single-center cohort study"],"prefix":"10.1007","volume":"489","author":[{"given":"Mehmet Berkay","family":"Ozata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Aytac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim Halil","family":"Erdogdu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Alkan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0598-7284","authenticated-orcid":false,"given":"Ozgur","family":"Tanriverdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,7]]},"reference":[{"issue":"1","key":"4329_CR1","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.21871","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A (2025) Cancer statistics, 2025. CA Cancer J Clin 75(1):10\u201345. https:\/\/doi.org\/10.3322\/caac.21871","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"4329_CR2","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/j.gendis.2022.07.023","volume":"10","author":"H Padinharayil","year":"2022","unstructured":"Padinharayil H, Varghese J, John MC, Rajanikant GK, Wilson CM, Al-Yozbaki M et al (2022) Non-small cell lung carcinoma (NSCLC): Implications on molecular pathology and advances in early diagnostics and therapeutics. Genes Dis 10(3):960\u2013989. https:\/\/doi.org\/10.1016\/j.gendis.2022.07.023","journal-title":"Genes Dis"},{"key":"4329_CR3","doi-asserted-by":"publisher","first-page":"1611715","DOI":"10.3389\/pore.2024.1611715","volume":"30","author":"G G\u00e1lffy","year":"2024","unstructured":"G\u00e1lffy G, Mor\u00f3cz \u00c9, Korompay R, H\u00e9cz R, Bujdos\u00f3 R, Pusk\u00e1s R et al (2024) Targeted therapeutic options in early and metastatic NSCLC-overview. Pathol Oncol Res. 30:1611715. https:\/\/doi.org\/10.3389\/pore.2024.1611715","journal-title":"Pathol Oncol Res."},{"issue":"1","key":"4329_CR4","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1038\/s41392-024-01823-2","volume":"9","author":"Y Zhou","year":"2024","unstructured":"Zhou Y, Tao L, Qiu J, Xu J, Yang X, Zhang Y et al (2024) Tumor biomarkers for diagnosis, prognosis and targeted therapy. Signal Transduct Target Ther 9(1):132. https:\/\/doi.org\/10.1038\/s41392-024-01823-2","journal-title":"Signal Transduct Target Ther"},{"issue":"16","key":"4329_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16162882","volume":"16","author":"A Rina","year":"2024","unstructured":"Rina A, Maffeo D, Minnai F, Esposito M, Palmieri M, Serio VB et al (2024) The genetic analysis and clinical therapy in lung cancer: current advances and future directions. Cancers 16(16):2882. https:\/\/doi.org\/10.3390\/cancers16162882","journal-title":"Cancers"},{"issue":"1","key":"4329_CR6","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/s41392-024-01979-x","volume":"9","author":"B Wu","year":"2024","unstructured":"Wu B, Zhang B, Li B, Wu H, Jiang M (2024) Cold and hot tumors: from molecular mechanisms to targeted therapy. Signal Transduct Target Ther 9(1):274. https:\/\/doi.org\/10.1038\/s41392-024-01979-x","journal-title":"Signal Transduct Target Ther"},{"key":"4329_CR7","doi-asserted-by":"publisher","first-page":"e64399","DOI":"10.2196\/64399","volume":"11","author":"AJM Brnabic","year":"2025","unstructured":"Brnabic AJM, Lipkovich I, Kadziola Z, He D, Krein PM, Hess LM (2025) Next-Generation Sequencing-based testing among patients with advanced or metastatic nonsquamous non-small cell lung cancer in the United States: Predictive modeling using machine learning methods. JMIR Cancer 11:e64399. https:\/\/doi.org\/10.2196\/64399","journal-title":"JMIR Cancer"},{"issue":"4","key":"4329_CR8","doi-asserted-by":"publisher","first-page":"217","DOI":"10.5306\/wjco.v12.i4.217","volume":"12","author":"M Chevallier","year":"2021","unstructured":"Chevallier M, Borgeaud M, Addeo A, Friedlaender A (2021) Oncogenic driver mutations in non-small cell lung cancer: past, present and future. World J Clin Oncol 12(4):217\u2013237. https:\/\/doi.org\/10.5306\/wjco.v12.i4.217","journal-title":"World J Clin Oncol"},{"issue":"1","key":"4329_CR9","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1007\/s12672-025-01816-9","volume":"16","author":"N Ghoreyshi","year":"2025","unstructured":"Ghoreyshi N, Heidari R, Farhadi A, Chamanara M, Farahani N, Vahidi M et al (2025) Next-generation sequencing in cancer diagnosis and treatment: clinical applications and future directions. Discov Oncol 16(1):578. https:\/\/doi.org\/10.1007\/s12672-025-01816-9","journal-title":"Discov Oncol"},{"key":"4329_CR10","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.lungcan.2022.11.002","volume":"174","author":"D Heredia","year":"2022","unstructured":"Heredia D, Mas L, Cardona AF, Oyervides V, Motta Guerrero R, Galvez-Nino M et al (2022) A high number of co-occurring genomic alterations detected by NGS is associated with worse clinical outcomes in advanced EGFR-mutant lung adenocarcinoma: data from LATAM population. Lung Cancer 174:133\u2013140. https:\/\/doi.org\/10.1016\/j.lungcan.2022.11.002","journal-title":"Lung Cancer"},{"issue":"1","key":"4329_CR11","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1186\/s12916-025-04075-1","volume":"23","author":"Y Li","year":"2025","unstructured":"Li Y, Ni Y, Lv F, Shi Y, Chen Y, Wu X et al (2025) Molecular characteristics and responses to EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients with EGFR exon 19 insertions. BMC Med. 23(1):249. https:\/\/doi.org\/10.1186\/s12916-025-04075-1","journal-title":"BMC Med."},{"issue":"1","key":"4329_CR12","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1186\/s12885-025-14016-z","volume":"25","author":"FY Wang","year":"2025","unstructured":"Wang FY, Yeh YC, Lin SY, Wang SY, Chen PC, Chou TY et al (2025) Real-world application of targeted next-generation sequencing for identifying molecular variants in Asian non-small-cell lung cancer. BMC Cancer 25(1):715. https:\/\/doi.org\/10.1186\/s12885-025-14016-z","journal-title":"BMC Cancer"},{"issue":"12","key":"4329_CR13","doi-asserted-by":"publisher","first-page":"3758","DOI":"10.1021\/acsptsci.4c00530","volume":"7","author":"D Mehta","year":"2024","unstructured":"Mehta D, Rajput K, Jain D, Bajaj A, Dasgupta U (2024) Unveiling the role of mechanistic target of rapamycin kinase (MTOR) signaling in cancer progression and the emergence of MTOR inhibitors as therapeutic strategies. ACS Pharmacol Transl Sci. 7(12):3758\u20133779. https:\/\/doi.org\/10.1021\/acsptsci.4c00530","journal-title":"ACS Pharmacol Transl Sci."},{"issue":"9","key":"4329_CR14","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.3390\/genes11091045","volume":"11","author":"W Fu","year":"2020","unstructured":"Fu W, Hall MN (2020) Regulation of mTORC2 signaling. Genes (Basel) 11(9):1045. https:\/\/doi.org\/10.3390\/genes11091045","journal-title":"Genes (Basel)"},{"issue":"12","key":"4329_CR15","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1158\/2159-8290.CD-14-0971","volume":"5","author":"H Cheng","year":"2015","unstructured":"Cheng H, Zou Y, Ross JS, Wang K, Liu X, Halmos B et al (2015) RICTOR amplification defines a novel subset of patients with lung cancer who may benefit from treatment with mTORC1\/2 inhibitors. Cancer Discov. 5(12):1262\u20131270. https:\/\/doi.org\/10.1158\/2159-8290.CD-14-0971","journal-title":"Cancer Discov."},{"issue":"3","key":"4329_CR16","doi-asserted-by":"publisher","first-page":"543","DOI":"10.3390\/cancers16030543","volume":"16","author":"F Szalai","year":"2024","unstructured":"Szalai F, Sztankovics D, Krencz I, Moldvai D, P\u00e1pay J, Sebesty\u00e9n A et al (2024) Rictor-A mediator of progression and metastasis in lung cancer. Cancers (Basel). 16(3):543. https:\/\/doi.org\/10.3390\/cancers16030543","journal-title":"Cancers (Basel)."},{"key":"4329_CR17","doi-asserted-by":"publisher","first-page":"1611643","DOI":"10.3389\/pore.2024.1611643","volume":"30","author":"D Sztankovics","year":"2024","unstructured":"Sztankovics D, Moldvai D, Pet\u0151v\u00e1ri G, Dank\u00f3 T, Szalai F, Miyaura R et al (2024) mTOR hyperactivity and RICTOR amplification as targets for personalized treatments in malignancies. Pathol Oncol Res 30:1611643. https:\/\/doi.org\/10.3389\/pore.2024.1611643","journal-title":"Pathol Oncol Res"},{"key":"4329_CR18","doi-asserted-by":"publisher","first-page":"1611593","DOI":"10.3389\/pore.2024.1611593","volume":"30","author":"I Krencz","year":"2024","unstructured":"Krencz I, Sztankovics D, Sebesty\u00e9n A, P\u00e1pay J, Dank\u00f3 T, Moldvai D et al (2024) RICTOR amplification is associated with Rictor membrane staining and does not correlate with PD-L1 expression in lung squamous cell carcinoma. Pathol Oncol Res 30:1611593. https:\/\/doi.org\/10.3389\/pore.2024.1611593","journal-title":"Pathol Oncol Res"},{"issue":"1","key":"4329_CR19","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s12943-018-0794-0","volume":"17","author":"A Jebali","year":"2018","unstructured":"Jebali A, Dumaz N (2018) The role of RICTOR downstream of receptor tyrosine kinase in cancers. Mol Cancer 17(1):39. https:\/\/doi.org\/10.1186\/s12943-018-0794-0","journal-title":"Mol Cancer"},{"issue":"18","key":"4329_CR20","doi-asserted-by":"publisher","first-page":"2090","DOI":"10.3390\/diagnostics14182090","volume":"14","author":"M Beckert","year":"2024","unstructured":"Beckert M, Meyer C, Papadopoulos T, Levidou G (2024) Application of the 5th WHO Guidelines for the diagnosis of lung carcinoma in small lung biopsies in a Tertiary Care Center: is insecurity of pathologists for the accurate diagnosis justified? Diagnostics (Basel) 14(18):2090. https:\/\/doi.org\/10.3390\/diagnostics14182090","journal-title":"Diagnostics (Basel)"},{"issue":"2","key":"4329_CR21","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1177\/10668969231171940","volume":"32","author":"LM Briski","year":"2024","unstructured":"Briski LM, Aron M, Epstein JI, Russell DH, Assarzadegan N, Delma KS et al (2024) Patterns of immunoreactivity with TTF-1 antibodies 8G7G3\/1 and SPT24 suggest distinct immunoprofiles between most pulmonary and nonpulmonary small cell carcinomas. Int J Surg Pathol 32(2):230\u2013238","journal-title":"Int J Surg Pathol"},{"issue":"2","key":"4329_CR22","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1111\/1759-7714.12929","volume":"10","author":"W Li","year":"2019","unstructured":"Li W, Song P, Guo L, Liu X, Guo C, Ying J et al (2019) Clinical significance of \u2265 50% PD-L1 expression with the SP263 monoclonal antibody in non-small cell lung cancer patients. Thorac Cancer 10(2):175\u2013182. https:\/\/doi.org\/10.1111\/1759-7714.12929","journal-title":"Thorac Cancer"},{"issue":"5","key":"4329_CR23","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J et al (2015) ACMG Laboratory Quality Assurance Committee. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 17(5):405\u2013424. https:\/\/doi.org\/10.1038\/gim.2015.30","journal-title":"Genet Med"},{"issue":"11","key":"4329_CR24","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1038\/nbt.2696","volume":"31","author":"GM Frampton","year":"2013","unstructured":"Frampton GM, Fichtenholtz A, Otto GA, Wang K, Downing SR, He J et al (2013) Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol 31(11):1023\u20131031. https:\/\/doi.org\/10.1038\/nbt.2696","journal-title":"Nat Biotechnol"},{"issue":"1","key":"4329_CR25","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1097\/JTO.0b013e3181914111","volume":"4","author":"T Kosaka","year":"2009","unstructured":"Kosaka T, Yatabe Y, Onozato R, Kuwano H, Mitsudomi T (2009) Prognostic implication of EGFR, KRAS, and TP53 gene mutations in a large cohort of Japanese patients with surgically treated lung adenocarcinoma. J Thorac Oncol 4(1):22\u201329. https:\/\/doi.org\/10.1097\/JTO.0b013e3181914111","journal-title":"J Thorac Oncol"},{"issue":"74","key":"4329_CR26","doi-asserted-by":"publisher","first-page":"33995","DOI":"10.18632\/oncotarget.26129","volume":"9","author":"D Ruder","year":"2018","unstructured":"Ruder D, Papadimitrakopoulou V, Shien K, Behrens C, Kalhor N, Chen H et al (2018) Concomitant targeting of the mTOR\/MAPK pathways: novel therapeutic strategy in subsets of RICTOR\/KRAS-altered non-small cell lung cancer. Oncotarget 9(74):33995\u201334008. https:\/\/doi.org\/10.18632\/oncotarget.26129","journal-title":"Oncotarget"},{"key":"4329_CR27","doi-asserted-by":"publisher","first-page":"30","DOI":"10.3389\/fmolb.2020.00030","volume":"7","author":"C Zheng","year":"2020","unstructured":"Zheng C, Li X, Ren Y, Yin Z, Zhou B (2020) Coexisting EGFR and TP53 mutations in lung adenocarcinoma patients are associated with COMP and ITGB8 upregulation and poor prognosis. Front Mol Biosci 7:30. https:\/\/doi.org\/10.3389\/fmolb.2020.00030","journal-title":"Front Mol Biosci"},{"issue":"1","key":"4329_CR28","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1186\/s12885-020-06805-5","volume":"20","author":"K Qin","year":"2020","unstructured":"Qin K, Hou H, Liang Y, Zhang X (2020) Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis. BMC Cancer 20(1):328. https:\/\/doi.org\/10.1186\/s12885-020-06805-5","journal-title":"BMC Cancer"},{"key":"4329_CR29","doi-asserted-by":"publisher","unstructured":"Szwed A, Kim E, Jacinto E (2021) Regulation and metabolic functions of mTORC1 and mTORC2. Physiol Rev 101(3):1371\u20131426.  https:\/\/doi.org\/10.1152\/physrev.00026.2020","DOI":"10.1152\/physrev.00026.2020"},{"issue":"1","key":"4329_CR30","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1038\/s41420-024-02006-2","volume":"10","author":"R Su","year":"2024","unstructured":"Su R, Shao Y, Huang M, Liu D, Yu H, Qiu Y (2024) Immunometabolism in cancer: basic mechanisms and new targeting strategy. Cell Death Discov. 10(1):236. https:\/\/doi.org\/10.1038\/s41420-024-02006-2","journal-title":"Cell Death Discov."}],"container-title":["Virchows Archiv"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-025-04329-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00428-025-04329-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-025-04329-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T17:04:29Z","timestamp":1784048669000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00428-025-04329-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,7]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["4329"],"URL":"https:\/\/doi.org\/10.1007\/s00428-025-04329-6","relation":{},"ISSN":["0945-6317","1432-2307"],"issn-type":[{"value":"0945-6317","type":"print"},{"value":"1432-2307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,7]]},"assertion":[{"value":"12 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Medical Sciences Ethics Committee of Mugla Sitki Kocman University (Ethics Committee Approval Number: 240038, Date: September 11, 2024). All procedures were conducted following the ethical principles outlined in the Declaration of Helsinki.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Given the retrospective nature of the study, informed consent was waived by Medical Sciences Ethics Committee of Mugla Sitki Kocman University.","order":2,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}